Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LGNA-100
- Development stage
- Phase 1
- Lead developer
- Laguna Biotherapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
LGNA-100 (also known as QUAIL-100) is a first-in-class, attenuated live bacterial immunotherapy being developed by Laguna Biotherapeutics. Derived from *Listeria monocytogenes*, the drug is designed to harness the immune system's evolved response to the bacterium to robustly and durably expand and activate endogenous gamma delta (γδ) T cells. These activated γδ T cells can directly kill cancer cells and potentially enhance the efficacy of other immunotherapies. LGNA-100 is primarily being developed for the treatment of high-risk pediatric leukemias and myelodysplastic syndromes (MDS), particularly in patients following hematopoietic stem cell transplantation (HSCT). The FDA cleared the Investigational New Drug (IND) application for LGNA-100 in April 2026 for a Phase 1 study.
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on LGNA-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LGNA-100.